Clinical factors affecting renal response to dulaglutide. حسب Sungmin Kim (628527)

الموضوعات:

TREM1 inhibition decreases HIV mediated inflammatory cytokine production. حسب Jinhee Hyun (6900683)

DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. حسب Suelen Silva Gomes Dias (9928813)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. حسب Martin Selinger (3195987)

Effect of NAC on decreased MYH expression caused by arecoline in C2C12 cells. حسب Yi-Xuan Li (6633845)

Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. حسب Martin Selinger (3195987)

"…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …"

Inclusion of TPP side chains result in decreased melanoma cell mitochondria membrane potential, oxygen consumption, and increased DHE oxidation. حسب Kyle C. Kloepping (9928265)

"…(C) A375 melanoma cells were treated with 1.0 μM 5-, 8-, 10-, 12-,14-, or 16-TPP for 1.5 h and analyzed for DHE oxidation (* significant relative to control; p<0.05; n = 3 from 2 separate experiments; N = 6). …"

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات: